Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.

摘要

The development of efficient immunotherapies requires strong rationalization. We have recently implemented a large analysis of biomarkers in two studies involvingthe multi-peptide vaccine IMA901 and advanced renal cell cancer patients. Ourfindings demonstrate that the breadth of immune responses was associated withclinical benefits and that single-dose cyclophosphamide reduced the amount ofregulatory T cells and was associated with prolonged survival after vaccination.